• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Commentary

What’s the backup plan if a COVID-19 vaccine comes up short?

By
Hansa Bhargava
Hansa Bhargava
and
John Whyte
John Whyte
Down Arrow Button Icon
By
Hansa Bhargava
Hansa Bhargava
and
John Whyte
John Whyte
Down Arrow Button Icon
August 14, 2020, 12:01 PM ET
COVID-19-Vaccine Trial
HOLLYWOOD, FLORIDA - AUGUST 07: Lisa Taylor receives a COVID-19 vaccination from RN Jose Muniz with the help of Karenda Palmer, a staff member, as she takes part in a vaccine study at Research Centers of America on August 07, 2020 in Hollywood, Florida. Research Centers of America is currently conducting COVID-19 vaccine trials, implemented under the federal government's Operation Warp Speed program. The center is recruiting volunteers to participate in the clinical trials, working with the Federal Government and major Pharmaceutical Companies, that are racing to develop a vaccine to potentially prevent COVID-19. (Photo by Joe Raedle/Getty Images)Joe Raedle—Getty Images

A vaccine could be the savior against the coronavirus—and scientists are marshaling all their resources to find one. Over the past few weeks, eight vaccine candidates have progressed to advanced clinical trials.

But despite encouraging early data, some researchers and pharmaceutical experts have indicated that the predictions of a vaccine by early 2021 may be too optimistic, and arrival may still be a long way off. We need to start planning accordingly.

Add to this the concern that even if a vaccine is approved and manufactured quickly, many people won’t line up to take it. A new survey from WebMD found that only 42% of respondents said they planned to get a COVID-19 vaccine in the first year—and only 26% said they would get vaccinated in the first three months. Nearly 60% of respondents are either unsure they’ll get vaccinated or say they don’t plan to get it at all.

Additionally, even doctors haven’t reached a consensus on whether they’ll push their patients to get vaccinated. A new Medscape poll of more than 7,000 health care professionals (free registration required) found that only about half would recommend that patients get a vaccine when it’s first made available. Many respondents expressed concerns about the vaccine’s safety, fearing that adverse effects would outweigh the risk of COVID-19.

Wariness about vaccines isn’t unique to COVID-19. Less than 50% of Americans got the flu shot from 2018–2019. Thirty percent of seniors haven’t received the vaccine to protect against pneumonia. Even though the shingles vaccine is more than 90% effective, only 30% of people who meet criteria to receive it have done so.  

Some Americans suggest that we shouldn’t open schools until there’s a vaccine, or say they don’t feel comfortable returning to an office setting until there’s widespread vaccination. But that reality is some way off. Now is the time for us to move beyond an all-or-none approach where we put our lives on hold while we await a vaccine.

In order to do that, we must be transparent and have difficult conversations about risk. We need to address the tradeoff between a potential decrease in infection rates during a lockdown and potential business failures, job loss, and the impact of continued social isolation on substance abuse and mental health.

For example, CDC Director Dr. Robert R. Redfield recently spoke about the public health consequences of keeping kids out of school—including a recent increase in teen suicides and drug use. Particularly vulnerable communities may face possible food insecurity, academic delay, and even parental stress leading to child abuse.

We must also find ways to live with COVID-19. That requires more accurate, faster diagnostic tests, more robust research to understand how the infection spreads, as well as wider adoption of technologies to help with contact tracing. We need to let science lead the way.

We’re all hopeful that a COVID-19 vaccine is truly just around the corner. But please, let’s plan for the possibility that it won’t be the golden key to unlock us from our quarantines.

Hansa Bhargava, M.D., is senior medical director of WebMD. John Whyte, M.D., M.P.H., is chief medical officer of WebMD.

About the Authors
By Hansa Bhargava
See full bioRight Arrow Button Icon
By John Whyte
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

wolfgang
CommentaryLeadership
Europe doesn’t lack tech talent. Its leaders lack execution
By Wolfgang OelsMarch 3, 2026
5 hours ago
zuck
Commentarycyber
Boards aren’t ready for the AI age: What happens when your CEO gets deepfaked?
By James RichardsonMarch 3, 2026
7 hours ago
Europedigital transformation
Why Europe can lead in trusted, industrialized AI
By Dave McCannMarch 2, 2026
1 day ago
heitmann
CommentaryEntrepreneurship
Here’s how to build something that lasts, from the founder of a $300 million bootstrapped company that’s been growing for 28 years straight
By Tim HeitmannMarch 1, 2026
2 days ago
world's fair
CommentaryRobots
Something big is happening in AI, but panic is the wrong reaction
By Peter CappelliFebruary 28, 2026
3 days ago
putin
CommentaryRussia
Exclusive analysis: we looked at the 400 western firms still in Russia. Their paltry size strips Putin’s bluff bare naked
By Jeffrey Sonnenfeld, Stephen Henriques, Jake Waldinger and Giuseppe ScottoFebruary 27, 2026
4 days ago

Most Popular

placeholder alt text
Middle East
U.S. military gives Iran a taste of its own medicine with cheap copycat Shahed drones, while concern shifts to munitions supply in extended conflict
By Jason MaMarch 1, 2026
2 days ago
placeholder alt text
Success
Slack cofounder says workers and CEOs can get stuck doing 'fake' work like pre-meetings and slideshows
By Emma BurleighMarch 1, 2026
2 days ago
placeholder alt text
Middle East
Iran’s Islamic Revolutionary Guard controls a sprawling business empire that dominates the economy
By Jason MaMarch 2, 2026
22 hours ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, March 2, 2026
By Joseph HostetlerMarch 2, 2026
1 day ago
placeholder alt text
Success
MacKenzie Scott's close relationship with Toni Morrison long before Amazon put Scott on the path to give more than $1 billion to HBCUs
By Sasha RogelbergMarch 1, 2026
2 days ago
placeholder alt text
Health
Gen Z men are eating ‘boy kibble,’ the human equivalent to dog food, to load up on protein cheaply
By Jake AngeloMarch 1, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.